{
    "nct_id": "NCT03329846",
    "official_title": "A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated",
    "inclusion_criteria": "* 12 years and older unless not permitted by local regulations; in that case 18 years old and older\n* Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1\n* Histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) Staging Manual (8th edition)\n* Treatment-na√Øve participants (no prior systemic anticancer therapy for unresectable or metastatic melanoma)\n* Measurable disease per RECIST v1.1\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Active brain metastases or leptomeningeal metastases\n* Uveal or ocular melanoma\n* Participants with active, known, or suspected autoimmune disease\n* Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured\n\nOther protocol defined inclusion/exclusion criteria could apply",
    "miscellaneous_criteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com"
}